A Retrospective Study on the Influence of Siblings' Relatedness in Bolivian Patients with Chronic Chagas Disease

Overview

Journal Parasit Vectors

Publisher Biomed Central

Specialties Parasitology
Tropical Medicine

Date 2019 May 26

PMID 31126327

Authors

Juan Espinosa-Pereiro

Adrian Sanchez-Montalva

Fernando Salvador

Augusto Sao-Aviles

Elena Sulleiro

Israel Molina

Affiliations

Soon will be listed here.

Abstract

Background: Chagas disease is a protozoan infection caused by Trypanosoma cruzi. The disease has a chronic course in which 20-30% of the patients would develop progressive damage to the cardiovascular system and the gastrointestinal tube. We are still unable to predict who will develop end-organ damage but there are some acquired and genetic risk factors already known.

Results: We reviewed data from 833 patients with serologically confirmed Chagas disease in this retrospective study. Patients were classified as siblings or non-siblings (controls) and the results of pre-treatment blood PCR assay, end-organ damage (cardiac and/or gastrointestinal), and the presence of delayed type hypersensitivity (DTH) skin involvement in patients treated with benznidazole were analyzed. Siblings were grouped by family and we randomly generated groups of 2 or 3 persons with the remaining controls. We classified the results of each variable as concordant or discordant and compared the concordance in these results among the sibling groups with that among control groups. We identified 71 groups of siblings and randomly generated 299 groups of non-related patients. Pre-treatment blood PCR concordance was significantly higher (19%) among siblings compared to controls (P = 0.02), probably due to a higher frequency in pre-treatment positive results. No other statistically significant differences were found.

Conclusions: A significant difference was found in the concordance of pre-treatment blood PCR for T. cruzi among siblings compared to non-related controls.

References

Fabbro D, Danesi E, Olivera V, Codebo M, Denner S, Heredia C . Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis. 2014; 8(11):e3312. PMC: 4239005. DOI: 10.1371/journal.pntd.0003312. View

Riera C, Verges M, Iniesta L, Fisa R, Gallego M, Tebar S . Identification of a Western blot pattern for the specific diagnosis of Trypanosoma cruzi infection in human sera. Am J Trop Med Hyg. 2012; 86(3):412-6. PMC: 3284355. DOI: 10.4269/ajtmh.2012.11-0111. View

Marin-Neto J, Cunha-Neto E, Maciel B, Simoes M . Pathogenesis of chronic Chagas heart disease. Circulation. 2007; 115(9):1109-23. DOI: 10.1161/CIRCULATIONAHA.106.624296. View

Groh V, Steinle A, Bauer S, Spies T . Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science. 1998; 279(5357):1737-40. DOI: 10.1126/science.279.5357.1737. View

Piron M, Fisa R, Casamitjana N, Lopez-Chejade P, Puig L, Verges M . Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples. Acta Trop. 2007; 103(3):195-200. DOI: 10.1016/j.actatropica.2007.05.019. View

de Andrade J, Marin-Neto J, de Paola A, Vilas-Boas F, Oliveira G, Bacal F . [I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy]. Arq Bras Cardiol. 2011; 97(2 Suppl 3):1-48. View

Molina I, Salvador F, Sanchez-Montalva A, Trevino B, Serre N, Sao Aviles A . Toxic Profile of Benznidazole in Patients with Chronic Chagas Disease: Risk Factors and Comparison of the Product from Two Different Manufacturers. Antimicrob Agents Chemother. 2015; 59(10):6125-31. PMC: 4576116. DOI: 10.1128/AAC.04660-14. View

Zicker F, Smith P, Netto J, Oliveira R, Zicker E . Physical activity, opportunity for reinfection, and sibling history of heart disease as risk factors for Chagas' cardiopathy. Am J Trop Med Hyg. 1990; 43(5):498-505. DOI: 10.4269/ajtmh.1990.43.498. View

Cruz-Robles D, Reyes P, Monteon-Padilla V, Ortiz-Muniz A, Vargas-Alarcon G . MHC class I and class II genes in Mexican patients with Chagas disease. Hum Immunol. 2004; 65(1):60-5. DOI: 10.1016/j.humimm.2003.10.008. View

10.

Salvador F, Sanchez-Montalva A, Martinez-Gallo M, Sala-Cunill A, Vinas L, Garcia-Prat M . Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease. Clin Infect Dis. 2015; 61(11):1688-94. DOI: 10.1093/cid/civ690. View

11.

Perez-Molina J, Molina I . Chagas disease. Lancet. 2017; 391(10115):82-94. DOI: 10.1016/S0140-6736(17)31612-4. View

12.

KUSCHNIR E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J . [Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy]. Arq Bras Cardiol. 1985; 45(4):249-56. View

13.

Miles M, CEDILLOS R, Povoa M, De Souza A, Prata A, Macedo V . Do radically dissimilar Trypanosoma cruzi strains (zymodemes) cause Venezuelan and Brazilian forms of Chagas' disease?. Lancet. 1981; 1(8234):1338-40. DOI: 10.1016/s0140-6736(81)92518-6. View

14.

Layrisse Z, Fernandez M, Montagnani S, Matos M, Balbas O, Herrera F . HLA-C(*)03 is a risk factor for cardiomyopathy in Chagas disease. Hum Immunol. 2000; 61(9):925-9. DOI: 10.1016/s0198-8859(00)00161-0. View

15.

Rassi Jr A, Rassi S, Rassi A . Sudden death in Chagas' disease. Arq Bras Cardiol. 2001; 76(1):75-96. DOI: 10.1590/s0066-782x2001000100008. View

16.

Cunha-Neto E, Chevillard C . Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm. 2014; 2014:683230. PMC: 4152981. DOI: 10.1155/2014/683230. View

17.

Pinazo M, Munoz J, Posada E, Lopez-Chejade P, Gallego M, Ayala E . Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother. 2010; 54(11):4896-9. PMC: 2976114. DOI: 10.1128/AAC.00537-10. View

18.

Rassi Jr A, Rassi A, Marin-Neto J . Chagas heart disease: pathophysiologic mechanisms, prognostic factors and risk stratification. Mem Inst Oswaldo Cruz. 2009; 104 Suppl 1:152-8. DOI: 10.1590/s0074-02762009000900021. View

19.

Perez-Molina J, Perez A, Norman F, Monge-Maillo B, Lopez-Velez R . Old and new challenges in Chagas disease. Lancet Infect Dis. 2015; 15(11):1347-56. DOI: 10.1016/S1473-3099(15)00243-1. View

20.

Ayo C, Guimaraes Reis P, de Oliveira Dalalio M, Visentainer J, Oliveira C, Araujo S . Killer Cell Immunoglobulin-like Receptors and Their HLA Ligands are Related with the Immunopathology of Chagas Disease. PLoS Negl Trop Dis. 2015; 9(5):e0003753. PMC: 4433128. DOI: 10.1371/journal.pntd.0003753. View